290 related articles for article (PubMed ID: 18984771)
1. Identification of TACC1, NOV, and PTTG1 as new candidate genes associated with endocrine therapy resistance in breast cancer.
Ghayad SE; Vendrell JA; Bieche I; Spyratos F; Dumontet C; Treilleux I; Lidereau R; Cohen PA
J Mol Endocrinol; 2009 Feb; 42(2):87-103. PubMed ID: 18984771
[TBL] [Abstract][Full Text] [Related]
2. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
[TBL] [Abstract][Full Text] [Related]
3. Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation.
Vendrell JA; Magnino F; Danis E; Duchesne MJ; Pinloche S; Pons M; Birnbaum D; Nguyen C; Theillet C; Cohen PA
J Mol Endocrinol; 2004 Apr; 32(2):397-414. PubMed ID: 15072547
[TBL] [Abstract][Full Text] [Related]
4. SNAI2 upregulation is associated with an aggressive phenotype in fulvestrant-resistant breast cancer cells and is an indicator of poor response to endocrine therapy in estrogen receptor-positive metastatic breast cancer.
Alves CL; Elias D; Lyng MB; Bak M; Ditzel HJ
Breast Cancer Res; 2018 Jun; 20(1):60. PubMed ID: 29921289
[TBL] [Abstract][Full Text] [Related]
5. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
[TBL] [Abstract][Full Text] [Related]
6. A20/TNFAIP3, a new estrogen-regulated gene that confers tamoxifen resistance in breast cancer cells.
Vendrell JA; Ghayad S; Ben-Larbi S; Dumontet C; Mechti N; Cohen PA
Oncogene; 2007 Jul; 26(32):4656-67. PubMed ID: 17297453
[TBL] [Abstract][Full Text] [Related]
7. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
[TBL] [Abstract][Full Text] [Related]
8. Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen.
Habashy HO; Powe DG; Staka CM; Rakha EA; Ball G; Green AR; Aleskandarany M; Paish EC; Douglas Macmillan R; Nicholson RI; Ellis IO; Gee JM
Breast Cancer Res Treat; 2010 Jan; 119(2):283-93. PubMed ID: 19238537
[TBL] [Abstract][Full Text] [Related]
9. Efficient downregulation of ErbB-2 induces TACC1 upregulation in breast cancer cell lines.
Xiang J; Qiu W; Wang X; Zhou F; Wang Z; Liu S; Yue L
Oncol Rep; 2013 Apr; 29(4):1517-23. PubMed ID: 23354013
[TBL] [Abstract][Full Text] [Related]
10. CtIP silencing as a novel mechanism of tamoxifen resistance in breast cancer.
Wu M; Soler DR; Abba MC; Nunez MI; Baer R; Hatzis C; Llombart-Cussac A; Llombart-Bosch A; Aldaz CM
Mol Cancer Res; 2007 Dec; 5(12):1285-95. PubMed ID: 18171986
[TBL] [Abstract][Full Text] [Related]
11. Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes.
McClelland RA; Manning DL; Gee JM; Anderson E; Clarke R; Howell A; Dowsett M; Robertson JF; Blamey RW; Wakeling AE; Nicholson RI
Breast Cancer Res Treat; 1996; 41(1):31-41. PubMed ID: 8932874
[TBL] [Abstract][Full Text] [Related]
12. Oligonucleotide microarray analysis of estrogen receptor alpha-positive postmenopausal breast carcinomas: identification of HRPAP20 and TIMELESS as outstanding candidate markers to predict the response to tamoxifen.
Tozlu-Kara S; Roux V; Andrieu C; Vendrell J; Vacher S; Lazar V; Spyratos F; Tubiana-Hulin M; Cohen P; Dessen P; Lidereau R; Bièche I
J Mol Endocrinol; 2007 Oct; 39(4):305-18. PubMed ID: 17909269
[TBL] [Abstract][Full Text] [Related]
13. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
Hole S; Pedersen AM; Hansen SK; Lundqvist J; Yde CW; Lykkesfeldt AE
Int J Oncol; 2015 Apr; 46(4):1481-90. PubMed ID: 25625755
[TBL] [Abstract][Full Text] [Related]
14. RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity.
Barua D; Sultana A; Islam MN; Cox F; Gupta A; Gupta S
BMC Cancer; 2023 Mar; 23(1):288. PubMed ID: 36997866
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of SIAH2, an ubiquitin E3 ligase, is associated with resistance to endocrine therapy in breast cancer.
Jansen MP; Ruigrok-Ritstier K; Dorssers LC; van Staveren IL; Look MP; Meijer-van Gelder ME; Sieuwerts AM; Helleman J; Sleijfer S; Klijn JG; Foekens JA; Berns EM
Breast Cancer Res Treat; 2009 Jul; 116(2):263-71. PubMed ID: 18629630
[TBL] [Abstract][Full Text] [Related]
16. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
[TBL] [Abstract][Full Text] [Related]
17. LAMP3 is involved in tamoxifen resistance in breast cancer cells through the modulation of autophagy.
Nagelkerke A; Sieuwerts AM; Bussink J; Sweep FC; Look MP; Foekens JA; Martens JW; Span PN
Endocr Relat Cancer; 2014 Feb; 21(1):101-12. PubMed ID: 24434718
[TBL] [Abstract][Full Text] [Related]
18. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
Newby JC; Johnston SR; Smith IE; Dowsett M
Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen induces a pluripotency signature in breast cancer cells and human tumors.
Notas G; Pelekanou V; Kampa M; Alexakis K; Sfakianakis S; Laliotis A; Askoxilakis J; Tsentelierou E; Tzardi M; Tsapis A; Castanas E
Mol Oncol; 2015 Nov; 9(9):1744-59. PubMed ID: 26115764
[TBL] [Abstract][Full Text] [Related]
20. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
